Currently, numerous RIPK1 inhibitors are in different phases of clinical trials for a spectrum of human inflammatory diseases, ranging from rheumatoid arthritis, cutaneous lupus erythematosus, ulcerative colitis, SARS-CoV-2 infection, to Alzheimer’s disease and ALS (Table 1) [125,126,127,128,129,130,131] (ClinicalTrials.gov). Here, RIPK1 is linked to cutaneous lupus erythematosus.